IXICO PLC (GB:IXI)
LSE:IXI
Want to see GB:IXI full AI Analyst Report?
Earnings Data
Report Date
Dec 08, 2026Before Open (Confirmed)
Period Ending
2026 (Q4)Consensus EPS Forecast
―Last Year’s EPS
>-0.01Same Quarter Last Year
Based on 0 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed solid operational progress and strong commercial momentum: double-digit revenue growth (23% in H1), a record GBP 18.1m order book providing 95% coverage of FY26 guidance, improved gross margin (53%), a narrowed EBITDA loss (GBP 0.5m), a successful GBP 10m capital raise and a strategic Medidata partnership that supports productization and scaling. Offsetting these positives are continuing near-term losses, timing risk for TechBio-derived recurring revenue due to productization and regulatory timelines, some exposure to trial descopes/cancellations and the need to convert an increasingly promising pipeline into contracted revenue in large indications like Alzheimer’s and Parkinson’s. Overall, the momentum and balance sheet reinforcement from the capital raise materially outweigh the near-term investment-driven drawbacks, but investors should note the multi-year horizon to realize TechBio recurring revenue and the stated 2029 target for sustained profitability.Company Guidance
Strong Revenue Growth
Revenue for H1 FY26 was GBP 3.9m, a 23% increase versus H1 FY25, ahead of the company's 15% full-year growth guidance.
Record Order Book and Visibility
Order book reached GBP 18.1m (record), up 31% since the end of FY25 and 38% versus H1 FY25; book-to-bill ratio of 1.75. The order book covers approximately 95% of FY26 revenue guidance (GBP 7.5m), providing strong near-term revenue visibility.
Improved Margins and Operational Leverage
Gross margin improved to 53% in H1 FY26, driven by higher revenue volume, favorable sales mix and more Phase II/III work with higher automated-analysis content that yields higher margins.
Reduced EBITDA Loss and Pathway to Profitability
EBITDA loss narrowed to GBP 0.5m for H1 FY26 (reduction on prior periods) despite continued investment; management targets sustainable profitability and positive cash generation by 2029.
Successful Capital Raise Strengthens Balance Sheet
Completed a GBP 10m capital raise (slightly oversubscribed) with net proceeds of GBP 9.4m. Cash at period end was GBP 1.7m and increased to GBP 10.8m at end-April after the raise, enabling planned technology and commercial investments.
Strategic Partnership with Medidata
Entered a collaboration with Medidata (Dassault) to integrate IXI analytics with the Rave platform — a channel to scale through a partner that serves ~80% of FDA-approved drug development programs, validating productization strategy.
Product and Tech Roadmap (TechBio Strategy)
Launched a TechBio roadmap to productize the IXI platform (AI-native, cloud-based on Microsoft Azure), target 2–3 commercially validated products by year-end, pursue SaaS/licensing/recurring revenue, and plan regulatory pathway toward software-as-a-medical-device (18+ month timeline once started).
Commercial and Scientific Momentum
Pipeline diversification with Alzheimer's representing ~50% of pipeline volume; order book composition includes ~20% Alzheimer’s, increased Phase II/III projects, six new KOL endorsements (including Michael J. Fox Foundation support) and expanded US commercial presence (CCO based in Boston).
GB:IXI Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
GB:IXI Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 19, 2026 | 6.75 p | 8.63 p | +27.78% |
Dec 09, 2025 | 10.75 p | 12.25 p | +13.95% |
May 20, 2025 | 9.00 p | 11.25 p | +25.00% |
Dec 04, 2024 | 12.25 p | 10.75 p | -12.24% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does IXICO PLC (GB:IXI) report earnings?
IXICO PLC (GB:IXI) is schdueled to report earning on Dec 08, 2026, Before Open (Confirmed).
What is IXICO PLC (GB:IXI) earnings time?
IXICO PLC (GB:IXI) earnings time is at Dec 08, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of IXICO PLC stock?
The P/E ratio of IXICO plc is N/A.
What is GB:IXI EPS forecast?
Currently, no data Available